Patricia R Blank

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. pmc Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
    BMC Public Health 8:272. 2008
  2. doi request reprint Population access to new vaccines in European countries
    Patricia R Blank
    Institute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
    Vaccine 31:2862-7. 2013
  3. pmc Attitudes of the general public and general practitioners in five countries towards pandemic and seasonal influenza vaccines during season 2009/2010
    Patricia R Blank
    Institute of Social and Preventive Medicine, Medical Economics, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e45450. 2012
  4. doi request reprint The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly
    Patricia Blank
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Hum Vaccin Immunother 8:328-35. 2012
  5. doi request reprint Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland
    Patricia R Blank
    Institute of Social and Preventive Medicine, Medical Economics, University of Zurich, Switzerland
    Vaccine 30:4267-75. 2012
  6. pmc Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis
    Mazda Farshad
    Department of Orthopedic Surgery, University of Zurich, Balgrist University Hospital, Zurich, Switzerland
    BMC Health Serv Res 11:317. 2011
  7. doi request reprint Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    Pharmacoeconomics 28:629-47. 2010
  8. doi request reprint Increasing influenza vaccination coverage in recommended population groups in Europe
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
    Expert Rev Vaccines 8:425-33. 2009
  9. doi request reprint Vaccination coverage rates in eleven European countries during two consecutive influenza seasons
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, CH 8001 Zurich, Switzerland
    J Infect 58:446-58. 2009
  10. doi request reprint Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland
    Breast Cancer Res Treat 124:497-507. 2010

Collaborators

Detail Information

Publications20

  1. pmc Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
    BMC Public Health 8:272. 2008
    ....
  2. doi request reprint Population access to new vaccines in European countries
    Patricia R Blank
    Institute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
    Vaccine 31:2862-7. 2013
    ..In order to reduce the time to access for new, beneficial vaccines, the underlying vaccination recommendation, implementation and funding process needs to be understood and optimized, where necessary...
  3. pmc Attitudes of the general public and general practitioners in five countries towards pandemic and seasonal influenza vaccines during season 2009/2010
    Patricia R Blank
    Institute of Social and Preventive Medicine, Medical Economics, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e45450. 2012
    ..Vaccination coverage rates for seasonal influenza are not meeting national and international targets. Here, we investigated whether the 2009/2010 A/H1N1 pandemic influenza affected the uptake of influenza vaccines...
  4. doi request reprint The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly
    Patricia Blank
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Hum Vaccin Immunother 8:328-35. 2012
    ....
  5. doi request reprint Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland
    Patricia R Blank
    Institute of Social and Preventive Medicine, Medical Economics, University of Zurich, Switzerland
    Vaccine 30:4267-75. 2012
    ..9 Mio). The national immunisation programmes with PCV13 can be assumed cost saving when compared with the current vaccine PCV7 in Switzerland...
  6. pmc Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis
    Mazda Farshad
    Department of Orthopedic Surgery, University of Zurich, Balgrist University Hospital, Zurich, Switzerland
    BMC Health Serv Res 11:317. 2011
    ..A critical evaluation of benefits and expenditures of both treatment options as in a cost effectiveness analysis seems well-suited to provide valuable information for treating physicians and healthcare policymakers...
  7. doi request reprint Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    Pharmacoeconomics 28:629-47. 2010
    ..Targeted therapies indicated both favourable and non-favourable ratios. Currently, trastuzumab is the only antibody-based targeted therapy that is established in the clinic for the metastatic setting...
  8. doi request reprint Increasing influenza vaccination coverage in recommended population groups in Europe
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
    Expert Rev Vaccines 8:425-33. 2009
    ....
  9. doi request reprint Vaccination coverage rates in eleven European countries during two consecutive influenza seasons
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, CH 8001 Zurich, Switzerland
    J Infect 58:446-58. 2009
    ..The aims were to analyse vaccine uptake rates in the general population and in high-risk groups, including children, as well as to understand the principal drivers and barriers towards vaccination...
  10. doi request reprint Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland
    Breast Cancer Res Treat 124:497-507. 2010
    ..Predictive testing to identify adjuvant breast cancer patients who benefit from trastuzumab treatment is a clinical and economic necessity. Our model identifies FISH as the most cost-effective approach...
  11. doi request reprint KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben, Zurich, Switzerland
    Clin Cancer Res 17:6338-46. 2011
    ..Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients...
  12. doi request reprint Trends in influenza vaccination coverage rates in Germany over six seasons from 2001/02 to 2006/07
    Patricia R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    Med Klin (Munich) 103:761-8. 2008
    ..The aims of this study were to assess influenza vaccination coverage from 2001 to 2007 in Germany, to understand motivations and barriers to vaccination, and to identify vaccination intentions for season 2007/08...
  13. doi request reprint Influenza vaccination coverage rates in Austria in 2006/07 - a representative cross-sectional telephone survey
    Patricia R Blank
    European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Wien Med Wochenschr 158:583-8. 2008
    ..4%). The main reason for not getting vaccinated was indifference (>50%). Vaccination coverage in Austria in 2006/07 was low and far behind WHO objectives...
  14. ncbi request reprint Developments in influenza vaccination coverage in England, Scotland and Wales covering five consecutive seasons from 2001 to 2006
    Majbrit V Holm
    European Center of Pharmaceutical Medicine, University of Basel, CH 4031 Basel, Switzerland
    Vaccine 25:7931-8. 2007
    ..Although Great Britain complies with national and international goals of vaccination coverage rates effort is needed to ensure high vaccination coverage rates at the same level in the future...
  15. pmc Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006
    Majbrit V Holm
    European Center of Pharmaceutical Medicine, University of Basel, 4031 Basel, Switzerland
    BMC Infect Dis 7:144. 2007
    ..To assess influenza vaccination coverage from 2001 to 2006 in Germany, to understand drivers and barriers to vaccination and to identify vaccination intentions for season 2006/07...
  16. pmc Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective
    Patricia R Blank
    ECPM Institute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
    BMC Dermatol 10:4. 2010
    ..We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland...
  17. ncbi request reprint Influenza vaccination coverage rates in Europe--covering five consecutive seasons (2001-2006) in five countries
    Majbrit V Holm
    European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Influenza Other Respi Viruses 1:215-21. 2007
    ..To understand potential drivers and barriers to influenza vaccination in the general population...
  18. ncbi request reprint The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus
    Thomas D Szucs
    Institute of Pharmaceutical Medicine ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland
    Eur J Clin Pharmacol 70:983-90. 2014
    ..We therefore sought to use EVITA to evaluate eight novel agents recently introduced to clinical practice or in late-stage trials for the treatment of prostate cancer, metastatic melanoma, or systemic lupus erythematosus (SLE)...
  19. ncbi request reprint Stroke in Switzerland: social determinants of treatment access and cost of illness
    Philippe Snozzi
    University of Zurich, Institute of Social and Preventive Medicine, Medical Economics, Zurich, Switzerland Electronic address
    J Stroke Cerebrovasc Dis 23:926-32. 2014
    ..Special attention was paid to possible correlations between epidemiologic indicators, sociodemographic variables, resource use, and costs...
  20. pmc Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa
    Lukas L Widmer
    University of Zurich Centre for Travel Medicine, WHO Collaborating Centre for Travellers Health, Hirschengraben 84, 8001 Zurich, Switzerland
    BMC Infect Dis 10:279. 2010
    ....